HUTCHMED (China) Limited HCM
At closeNov 3, 2026, 4:08 PM EST
After hours · Nov 3, 4:08 PM ET
- YTD
- -1.88%
- 1 year
- -14.57%
- Market cap
- 2.27B
- Revenue (ttm)
- 549.12M
- Profit margin
- 3.26%
- EPS (ttm)
- 0.10
- Shares out
- 173.81M
- P/E ratio
- 130.80
- Forward P/E
- 50.46
- YTD return
- -1.88%
- 1-year return
- -14.57%
- Volume
- 28.85K
- Avg volume
- 66.23K
- Open
- 13.25
- Previous close
- 13.27
- Day's range
- 13.02 – 13.25
- 52-week range
- 9.77 – 16.33
- Beta
- 0.49
- Analysts
- Strong Buy
- Price target
- 21.14 (+61.6%)
- Earnings date
- Mar 4, 2027
1m 0.00 (0.00%)
Key statistics
- Enterprise value
- 1.04B
- PEG ratio
- 0.00
- Price / sales
- 4.14
- Price / book
- 1.80
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Revenue growth
- 0.20%
- Free cash flow
- -18.88M
- Total cash
- 1.38B
- Total debt
- 94.51M
- Return on equity
- 1.46%
- Short % of float
- 0.25%
- 50-day average
- 13.66
- 200-day average
- 13.21
Analyst view
Consensus: strong buy
- Target (low)
- 13.60
- Target (mean)
- 21.14
- Target (high)
- 33.27
- Strong buy1
- Buy9
- Hold1
- Sell0
- Strong sell0
Next earnings
Mar 4, 2027
Expected Mar 4, 2027. Consensus EPS estimate 0.00.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Mar 4, 2027 | Dec 30, 2026 | 0.21 | — | — | — |
| Jul 30, 2026 | Jun 30, 2026 | 0.145 | 0.046 | -0.10 | -68.28% |
| Jul 2, 2026 | Mar 31, 2026 | -0.35806 | 0.046 | +0.40 | +112.85% |
| Mar 5, 2026 | Dec 31, 2025 | 2.50 | 0.0005 | -2.50 | -99.98% |
| Aug 7, 2025 | Jun 30, 2025 | 1.46 | 2.60 | +1.14 | +78.08% |
| Jul 2, 2025 | Mar 31, 2025 | -0.31695 | 1.35 | +1.67 | +525.93% |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Jul 23, 2026 | Goldman Sachs | main | Neutral | Neutral |
| Jul 7, 2026 | B of A Securities | main | Buy | Buy |
| Mar 10, 2026 | B of A Securities | main | Buy | Buy |
| Sep 22, 2025 | Morgan Stanley | down | Equal-Weight | Underweight |
| Jul 22, 2025 | B of A Securities | main | Buy | Buy |
| Aug 1, 2024 | Goldman Sachs | main | Neutral | Neutral |
About HUTCHMED (China) Limited
HUTCHMED (China) Limited, together with its subsidiaries, discovers, develops, and commercializes targeted therapeutics and immunotherapies to treat cancer and immunological diseases in Hong Kong, the United States, and internationally. It provides Fruquintinib, a selective and potent oral inhibitor of vascular endothelial growth factor receptors for treatment of colorectal cancer (CRC), breast cancer, gastric cancer (GC), microsatellite stable-CRC endometrial cancer (EMC), non-small cell lung cancer (NSCLC), renal cell carcinoma (RCC), endometrial cancer (EMC); and Savolitinib, a potent and selective inhibitor of mesenchymal-epithelial transition receptor to treat NSCLC, papillary RCC, and GC. It also develops Surufatinib to treat pancreatic neuroendocrine tumor (NET), non pancreatic NET, and pancreatic ductal adenocarcinoma; Sovleplenib, to treat immune thrombocytopenic purpura and warm autoimmune hemolytic anemia; and Tazemetostat, a treatment for epithelioid sarcoma and follicular lymphoma; Fanregratinib that treats intrahepatic cholangiocarcinoma; and Ranosidenib, a novel dual-inhibitor of dehydrogenase-1 and isocitrate dehydrogenase-2 enzymes to treat acute myeloid leukemia (AML). In addition, the company is developing HMPL-760, which is in phase I and II clinical trial to treat relapsed and/or refractory diffuse large B cell lymphoma, chronic lymphocytic leukemia, small lymphocytic lymphoma, and other B-NHL; HMPL-506 to treat Mixed-lineage leukemia-rearrange/rearrangement and nucleophosmin 1-mutantAML. It has collaboration agreements with AstraZeneca AB (publ), Lilly (Shanghai) Management Company Limited, Takeda, Inmagene Biopharmaceuticals Co. Ltd., Innovent Biologics Co., Inc., and Epizyme, Inc., and Epizyme, Inc. The company was formerly known as Hutchison China MediTech Limited and changed its name to HUTCHMED (China) Limited in May 2021. HUTCHMED (China) Limited was incorporated in 2000 and is headquartered in Hong Kong, Hong Kong.
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- Country
- Hong Kong
- Website
- hutch-med.com
News
HUTCHMED Announces Regulatory Filings Accepted for Review for ORPATHYS® plus TAGRISSO® in MET-Driven EGFR-Mutated Lung Cancer in Europe and Japan 
Braveheart Bio to Host Webinar – HCM Spotlight: Advancing a Next-Generation Cardiac Myosin Inhibitor – with Key Opinion Leader Discussion on November 6, 2026 
Reported Earlier, HUTCHMED Says FDA Grants Orphan Drug Designation To Sovleplenib For Primary Immune Thrombocytopenia, Making It Eligible For 7 Years Of US Market Exclusivity 
HUTCHMED Announces Sovleplenib Granted US FDA Orphan Drug Designation for Primary Immune Thrombocytopenia 
Firms in Asia Pacific Embrace Unified Workday Platforms 
Save the Date: HUTCHMED to Host Expert Insights Event on Recent Savolitinib Clinical Data in Non-Small Cell Lung Cancer 
AI Brings U.S. Enterprises More Value from Workday 
HUTCHMED Highlights SANOVO Phase III Data At ESMO, ORPATHYS Plus TAGRISSO Cuts Progression Or Death Risk 44% In First-Line EGFR-Mutated Lung Cancer, Improves OS; China Supplemental NDA Planned 
HUTCHMED Highlights SANOVO Phase III Data for ORPATHYS® plus TAGRISSO® in First-Line EGFR-Mutated Lung Cancer Presented at ESMO Congress 2026 
HUTCHMED Announced At ESMO Sunday, SAFFRON Phase III Shows ORPATHYS Plus TAGRISSO Cut Progression Or Death Risk 45%, Death Risk 32% Versus Chemotherapy In MET-Driven EGFR-Mutated Lung Cancer
Your note
Sign in to keep a note on HCM — it syncs with the Stock Master app.
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Schroder Investment Management Group | 0.85% | 1,477,494 | 19.33M | Jun 29, 2026 |
| Allianz Asset Management GmbH | 0.39% | 674,511 | 8.82M | Jun 29, 2026 |
| State Street Corporation | 0.18% | 313,611 | 4.10M | Jun 29, 2026 |
| Aia Group Ltd | 0.15% | 266,658 | 3.49M | Sep 29, 2026 |
| M&G Plc | 0.14% | 242,791 | 3.18M | Jun 29, 2026 |
| Amundi | 0.12% | 204,385 | 2.67M | Jun 29, 2026 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Steward Funds Inc-Steward Values Enhanced International Fund | 0.05% | 84,097 | 1.10M | Jul 30, 2026 |
| SPDR INDEX SHARES Fd.S-State Street SPDR PORT. Developed World ex-US E | 0.04% | 71,242 | 931.85K | Sep 29, 2026 |
| SPDR-EUROPE-SSgA SPDR ETFS Europe I-State Street SPDR MSCI Emerging Ma | 0.03% | 44,991 | 588.48K | Sep 29, 2026 |
| Fidelity Concord Street Trust-Fidelity Nasdaq Composite Index Fund | 0.01% | 16,399 | 214.50K | Aug 30, 2026 |
| Dimensional ETF Trust-Dimensional World ex U.S. Core Equity 2 ETF | 0.00% | 2,110 | 27.60K | Jul 30, 2026 |
| Dimensional ETF Trust-Dimensional Emerging Markets Core Equity 2 ETF | 0.00% | 5,574 | 72.91K | Jul 30, 2026 |